Objective In rheumatoid arthritis (RA), MRI provides earlier detection of structural damage than radiography (X-ray) and more sensitive detection of intra-articular inflammation than clinical examination. This analysis was designed to evaluate the ability of early MRI findings to predict subsequent structural damage by X-ray. Methods Pooled data from four randomised controlled trials (RCTs) involving 1022 RA hands and wrists in early and established RA were analysed. X-rays were scored using van der Heijde-modified or Genant-modified Sharp methods. MRIs were scored using Outcome Measures in Rheumatology (OMERACT) RA MRI Score (RAMRIS). Data were analysed at the patient level using multivariable logistic regression and receiver operating characteristic curve analyses. Results Progression of MRI erosion scores at Weeks 12 and 24 predicted progression of X-ray erosions at Weeks 24 and 52, with areas under the curve (AUCs) of 0.64 and 0.74, respectively. 12-week and 24-week changes in MRI osteitis scores were similarly predictive of 24-week and 52-week X-ray erosion progressions; pooled AUCs were 0.78 and 0.77, respectively. MRI changes in synovitis at Weeks 12 and 24 also predicted progression of X-ray joint damage (erosion and joint-space narrowing) at Weeks 24 and 52 (AUCs=0.72 and 0.65, respectively). Conclusions Early changes in joint damage and inflammation detected with MRI predict changes in joint damage evident on subsequent X-rays. These findings support the use of MRI as a valid method for monitoring structural damage in short-duration RCTs.
INTRODUCTION
Radiography has been the standard for assessing structural damage in rheumatoid arthritis (RA) randomised controlled trials (RCTs) for many years. Recently, however, discriminating differences in the rates of progression of X-ray damage between treatment arms has become more challenging. The most important reason for this has been recognition that exposing subjects with active RA to placebo for longer than 12 weeks is unethical. 1 Accordingly, current US Food and Drug Administration (FDA) guidance states that trials of >12 weeks should include an active comparator as the control or make provisions for rescue therapy. 2 This poses a major obstacle to using X-ray in RCTs, because 24 weeks is typically necessary for radiographic demonstration of inhibition of structural progression, and longer treatment duration and larger numbers are necessary to resolve differences between active comparators. A method that more reliably detects structural progression within a 3-month time frame would therefore be helpful.
MRI has demonstrated criterion validity for osteitis and synovitis with histology and construct validity for erosions when compared with CT. 3 4 Numerous studies have demonstrated MRI to be more sensitive than X-ray in detecting joint damage and to detect synovitis and osteitis more sensitively than clinical examination does. Consequently, there has been a rapid increase in the use of MRI in RA RCTs over the past decade. 4 A recent report by the imaging subcommittee of the American College of Rheumatology (ACR) Clinical Trials Task Force 5 concluded that MRI met the Outcome Measures in Rheumatology (OMERACT) validation filter for 'truth, discrimination and feasibility'. 6 7 It concluded that 'among all of the currently available imaging modalities that have been validated with supportive data, MRI best serves the purpose of achieving sensitive ascertainment of structural damage in RCTs while also providing objective measures of inflammatory predictors of damage'. The report proposed analysing recently completed RCTs that included both MRI and X-ray assessments to evaluate the predictive validity of MRI.
Accordingly, under the auspices of OMERACT, a task force of the members of the imaging subcommittee of the ACR Clinical Trials Task Force obtained and pooled data from four RCTs that included both serial MRIs (baseline to 12 and/or 24 weeks) and X-rays (baseline to 24 and/or 52 weeks) to evaluate the ability of MRI to predict long-term structural damage on X-rays at the individual patient level using a statistical meta-analysis approach. The overall prediction performance for the patient population was evaluated by receiver operating characteristic (ROC) analysis.
METHODS
Data from four placebo RCTs ( 
as independent variables, where MRI 0 and Δ MRI were the baseline MRI measure and short-term change in MRI measure (erosion, osteitis or synovitis score), respectively, and x + represented the positive part of x. The dummy variables representing four RCTs accounted for different progression rates among patients enrolled in each trial. The association between baseline and short-term changes in MRI and longer-term X-ray progression was characterised by the estimated linear combination of the aforementioned basis functions. The ROC curves of the estimated linear combination and area under the curve (AUC) measurements were derived to determine the discriminative power of early changes in MRI endpoints for detecting subsequent structural progression by X-ray (AUC 0.5-0.7=poor, 0.7-0.8=acceptable, 0.8-0.9=excellent, >0.9=outstanding discrimination 5 ). All statistical analyses were performed using R-3.2.2 (The R foundation of Statistical Computing). Table 2 shows baseline X-ray and MRI scores of included patients from the four trials. The association between 12-week change in MRI erosion score and 24-week change in X-ray erosion score was examined in Trials A, B and C; Week 12 MRI data were not available for Trial D. After excluding patients with missing information, the proportions of patients with X-ray erosion progression >0.5 Sharp units at Week 24 in Trials A, B, C and the pooled cohort were 5.7% (10/166), 7.5% (69/ 855), 4.0% (22/534) and 6.1% (101/1555), respectively. ROC curve analysis of the prediction of X-ray progression at Week 24 based on a logistic regression model of baseline MRI erosion score and 12-week MRI progression in erosion score showed an AUC of 0.64 (95% CIs 0.54 to 0.75) (figure 1). Since we were interested in the predictive value of MRI beyond that due to varying progression rates across trials, we also performed a logistic regression with trial indicators as the only independent variables, and the AUC for this was only 0.51 (95% CI 0.41 to 0.62). Adjusted for trial indicators, the predictiveness of 12-week MRI changes combined with baseline MRI erosion scores was statistically significantly greater than that using the trial indicator alone ( p=0.031). The results by trial are shown in table 3.
RESULTS
The association between 24-week change in MRI erosion score and 52-week change in X-ray erosion score was examined using data from Trials B, C and D, as Trial A did not include Week 52 X-ray data (table 1). The proportions of patients with X-ray erosion progression at Week 52 were 9.0% (79/799), 4.3% (22/494), 7.8% (31/364) and 7.4% (132/ 1657) in Trials B, C, D and the pooled cohort, respectively. The AUC for predicting X-ray erosion progression at Week 52 based on MRI erosion scores at baseline and change at Week 24 was 0.74 (95% CI 0.66 to 0.82) (figure 1), which is considered acceptable. 5 If the logistic regression model considered only the trial as a variable, the AUC was poor (0.55; 95% CI 0.48 to 0.62). Adjusted for the trials, the predictiveness of 24-week change combined with baseline MRI erosion scores was highly statistically significantly greater than that using the trial indicator alone ( p<0.001). The results by trial are shown in table 3. The association between 12-week change in MRI osteitis score and 24-week change in X-ray erosion score was examined in Trials A, B and C; Trial D did not include osteitis scores. ROC analysis of the prediction of X-ray erosion progression at Week 24 based on 12-week MRI progression in osteitis showed a near excellent AUC of 0.78 (95% CI 0.70 to 0.86) (figure 1). As a reference, if only trial indicators were included as the predictors, the AUC of the logistic regression was very poor (0.51; 95% CI 0.41 to 0.62) suggesting that trial indicators alone are not predictive of X-ray erosion progression. Adjusted for the trials, the predictiveness of 12-week change and baseline MRI osteitis scores was highly statistically significantly greater than that using the trial indicator alone ( p<0.001). The association between 24-week change in MRI osteitis score and 52-week change in X-ray erosion score was examined in Trials B and C; Trial A lacked Week 52 X-ray data and Trial D lacked osteitis scores. The AUC for predicting X-ray erosion progression based on MRI osteitis scores at baseline and change at Week 24 was also near excellent (0.77; 95% CI0 .66 to 0.88) (figure 1) and again significantly greater ( p<0.001) than that observed if only the trial indicator was considered in the regression model (0.57; 95% CI 0.47 to 0.67).
The association between 12-week change in MRI synovitis score and 24-week change in X-ray total modified Sharp score was examined in Trials A, B and C, as Trial D did not include synovitis scores. At Week 24, 9.7% (17/159), 9.7% (90/834), 8.6% (48/508) and 9.4% (155/1501) of hands demonstrated X-ray progression in Trials A, B, C and the combined cohort, respectively. The AUC for predicting X-ray progression by MRI was acceptable (0.72; 95% CI 0.64 to 0.81) (figure 1) and significantly greater ( p<0.001) than that observed if only the trial was considered (0.55; 95% CI 0.47 to 0.63).
The association between 24-week change in MRI synovitis score and 52-week change in X-ray total modified Sharp score was examined in Trials B and C; Trial A did not include Week 52 X-ray data and Trial D did not include synovitis scores. At Week 52, 12.0% (105/773), 9.7% (50/466) and 11.1% (155/ 1239) of hands demonstrated X-ray progression in Trials B, C and the pooled cohort, respectively. The AUC of the ROC curve of MRI scores at baseline, Week 24 MRI changes and trial data predicting X-ray progression at 52 weeks was 0.65 (95% CI 0.55 to 0.75) (figure 1), compared with 0.51 (95% CI 0.42 to 0.59, p=0.063) if only the trial was considered in the regression model.
DISCUSSION
This analysis shows that changes in joint damage and inflammation detected with MRI as early as 12 weeks predict changes in joint damage evident on subsequent X-rays. The current analysis of pooled data from four RCTs that included both MRI and X-ray demonstrated that progression of MRI erosion scores at Weeks 12 and 24 predict progression of X-ray erosions at Weeks 24 and 52. Twelve-week and 24-week changes in MRI osteitis scores and synovitis scores were similarly predictive of 24-week and 52-week X-ray erosion progressions. These findings corroborate those of Baker et al 8 who further showed that MRI could allow a large reduction in the number of patients needed to assess structural damage in RA RCTs relative to that required with X-ray. 9 MRI has been used in 13 multicentre, placebo RCTs reported until now, [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] involving 10 different biological therapies. Nine RCTs 11 13-18 21 22 included follow-up intervals ≤12-16 weeks, and in seven of the nine, MRI demonstrated statistically significant inhibition of progression of bone erosions with active treatment compared with placebo within that time frame 14 15 17 18 or showed a lack of inhibition consistent with later X-ray data within the trial 16 22 or in subsequent trials. 23 Two of the nine RCTs were underpowered, but did show numerical suppression of erosion progression on early MRI (one RCT included only 20-21 patients per arm, and in contrast to the other RCTs, used only a single reader; 13 the second RCT included 28-35 patients per arm and showed numerical suppression of MRI erosion relative to placebo at 4 and 12 weeks and statistically significant suppression by 24 weeks). 21 Two of the nine RCTs discussed above 17 21 and an activecomparator trial 24 included MRI follow-up intervals of 4 weeks or less. Two of these trials demonstrated statistically significant suppression of synovitis and osteitis with MRI after only 2 weeks of active therapy, using 30-32 24 and 30-31 17 patients per arm, respectively. Both trials also showed inhibition of erosion with MRI at later time points. The third study 21 was underpowered for RA MRI Score(RAMRIS), as noted above, but showed numerical decreases in osteitis, synovitis as well as in erosion progression with treatment compared with placebo at 4 weeks.
There were a number of limitations to this analysis. Some trial data sets could not be included because they did not have earlier MRI followed by later X-ray outcomes. Of the three studies referred to above with MRI follow-up intervals <12 weeks, one 17 did not include X-ray and the other 24 used 0.2T rather than 1.5T MRI, so we were unable to examine whether very early MRI inflammation measures would be predictive of X-ray structural outcomes. Another limitation was that all but one of the four data sets rescued placebo patients with active therapy by 24 weeks, confounding analyses based on X-ray data over longer time intervals. This is, however, an issue for all modern RCTs given current restrictions on the duration of placebo treatment. If by 24 weeks the most rapidly progressing patients in the placebo arm of a trial have received rescue treatment, X-rays acquired at 24 weeks will underestimate the true placebo progression rate and thus the effect size of treatment. This limitation highlights why a method, such as MRI, that is sensitive enough to discriminate treatment effect within only 12 weeks, that is, before rescue treatment, is needed. Similarly, in this analysis, 24-week X-rays of patients rescued prior to 24 weeks will categorise some 12-week MRI progressors incorrectly as false positives and artificially reduce the AUC. Which patients received rescue therapy was known in two of the four RCTs analysed. However, removing these patients from analysis in one trial (A) did not significantly change the results (data not shown).
While the non-parametric spline fitting method used in this analysis is a flexible non-parametric approach, the resulting model may not have been optimal, and higher AUCs for the MRI measures could potentially have been attained by including, for example, additional information about the individual patients and more flexible basis functions of the MRI measures. Nevertheless, the estimated predictive value of MRI measures summarised by the AUCs of the ROC curves offers a conservative estimate of the true predictive value.
Lastly, we did not have access to MRI cartilage loss or MRI joint-space narrowing scores for any of the trials included in this analysis. However, the validity of assessing cartilage loss and joint-space narrowing with MRI has been well documented, [25] [26] [27] [28] and six RA RCTs have included MRI scoring of cartilage loss 14 17 18 22 26 or joint-space narrowing; 20 all have demonstrated good responsiveness.
In summary, on the basis of this analysis and previous studies, we conclude that MRI can detect progression of structural damage in RA RCTs as soon as 3 months and discriminate inhibition of progression of joint damage within this time frame in placebo-controlled trials with approximately 30-70 patients per treatment arm. We therefore recommend MRI as an imaging modality to assess inflammation and joint damage in shortduration RCTs in RA to reduce the number of patients and trial duration required to demonstrate inhibition of structural damage.
